iga

Documents about iga

• Atacicept in Multiple Glomerular Diseases#994779ClinicalTrials.gov
• A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy#832841ClinicalTrials.gov
• Probiotics in IgA Nephropathy#893908ClinicalTrials.gov
• Mediators of Loin Pain in IgA Nephropathy#852002ClinicalTrials.gov
• The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease#811431ClinicalTrials.gov
• Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy#887263ClinicalTrials.gov
• Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy#833050ClinicalTrials.gov
• Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy#855538ClinicalTrials.gov
• PS-002 for the Treatment of IgA Nephropathy in Adults#895528ClinicalTrials.gov
• Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis#414391ClinicalTrials.gov
• The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)#872599ClinicalTrials.gov
• Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy#387258ClinicalTrials.gov
• Baseline characteristics of the population-based cohort in Iga City - the Iga City Cohort Study#223941bioRxiv / medRxiv
• Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study#802070ClinicalTrials.gov
• Fecal Microbiota Transplantation for Refractory IgA Nephropathy#833142ClinicalTrials.gov
• A Trial of HRS-5965 Tablets in Primary IgA Nephropathy#982693ClinicalTrials.gov
• The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy#857467ClinicalTrials.gov
• Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy#871251ClinicalTrials.gov
• Pilot Study of Velcade® in IgA Nephropathy#802475ClinicalTrials.gov
• Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)#905241ClinicalTrials.gov
• Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD#803024ClinicalTrials.gov
• B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency#858054ClinicalTrials.gov
• Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy#871667ClinicalTrials.gov
• A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy#873477ClinicalTrials.gov
• Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy#897547ClinicalTrials.gov
• Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab#68405HAL (France)
• A Case of IgA Nephropathy With Membranoproliferative Glomerulonephritis-Like Features#194776OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Efficacy and Safety of Atacicept in IgA Nephropathy#855252ClinicalTrials.gov
• Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy#881571ClinicalTrials.gov
• IgA vasculitis associated with chronic myelomonocytic leukemia#442515HAL (France)
• Conclusions about a link between SAPHO syndrome, IgA nephropathy and dental amalgams can only be drawn after extensive analysis#11592HAL (France)
• Dr Spur's mystery case : new symptoms in a patient with selective IgA deficiency#393687University of Pretoria Repository
• A Study of YKST02 in Participants With Primary IgA Nephropathy#861586ClinicalTrials.gov
• A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.#867035ClinicalTrials.gov
• Huangkui capsule attenuates IgA nephropathy by modulating the TLR4/MyD88/NF-κB signaling pathway#382016Figshare
• Serum and Urinary sCD163 in IgA Nephropathy#801567ClinicalTrials.gov
• Universal STAR-T Cell Injection in Autoimmune Kidney Diseases#877776ClinicalTrials.gov
• Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults#5177Europe PMC
• Risk prediction in IgA nephropathy: from conventional models to machine learning, deep learning, and precision nephrology.#9717PubMed
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression#184704ClinicalTrials.gov
• Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data#830317ClinicalTrials.gov
• Identification of pyroptosis-related hub genes and immune cell infiltration in IgA nephropathy via bioinformatics analysis.#193906PubMed
• TCCON/py-ginput – ginput v1.6.3 release#226092CaltechDATA
• TCCON/py-ginput – ginput v1.6.2 release#259275CaltechDATA
• TCCON/py-ginput – ginput v1.5.1 release#259276CaltechDATA
• TCCON/py-ginput – ginput v1.6.1 release#259282CaltechDATA
• TCCON/py-ginput – ginput v1.6.0 release#259283CaltechDATA
• Risk prediction in IgA nephropathy: from conventional models to machine learning, deep learning, and precision nephrology#4655Europe PMC
• A nine-gene diagnostic model for IgA nephropathy based on multi-cohort machine learning: integrating gene expression and immunohistochemical validation.#9700PubMed
• Human Blood IgA + Memory B Cells Differ From IgG + B Cells by Expressing Gut‐Homing and Regulatory Markers#218060HAL (France)